Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 30, 2025Cardiovascular DiabetologyOpen Access

Effects of dapagliflozin on the progression of left ventricular dysfunction in type 2 diabetes mellitus: a randomized controlled trial

View Full Paper
Ask AI
Bookmark
Share

Why the study?

SGLT2 inhibitors reduce overt heart failure in T2DM, but the mechanism of their effect in stage B heart failure remains obscure.

Does dapagliflozin improve global longitudinal strain in patients with type 2 diabetes mellitus and stage B heart failure?

Population

139 patients with well-controlled T2DM and LV dysfunction

Comparison

Dapagliflozin 10 mg/day vs placebo

Design

Randomized controlled trial

Follow-up

24 months

Authors

TMThomas H. MarwickAHAmera HalabiCSCheng Hwee Soh

Discussion

Loading...

Member takes

Overview

Supports early SGLT2 inhibitor initiation to prevent progression in asymptomatic diabetic cardiomyopathy; extends proven heart.

Structured PICO

Does dapagliflozin improve global longitudinal strain in patients with type 2 diabetes mellitus and stage B heart failure?

P
Population
139 patients with well-controlled type 2 diabetes mellitus and left ventricular dysfunction (stage B heart failure), selected from a screened cohort of 262 individuals (mean age 73 ± 7 years, 159 women).
I
Intervention
Dapagliflozin 10 mg/day
C
Comparator
Placebo
O
Outcome
Global longitudinal strain (GLS) at 6 and 24 monthssurrogate

In patients with type 2 diabetes mellitus and stage B heart failure, dapagliflozin improved diastolic function, atrial function, and exercise capacity, but did not significantly change global longitudinal strain compared to placebo.

Cite This Study

Marwick et al. (2025) studied this question.

synapsesocial.com/papers/6a8d3b290b453ccb7788df84https://doi.org/10.1186/s12933-025-02796-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial2022 · 45 citations
  2. 2Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis2021 · 48 citations
  3. 3Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial2023 · 118 citations
  4. 4Use of the energy waveform electrocardiogram to detect subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus2024 · 6 citations
  5. 5Mechanisms of reduced peak oxygen consumption in subjects with uncomplicated type 2 diabetes2021 · 60 citations